Drug Approval | June 11, 2021
CSIR join hands with SUVEN Pharmaceuticals
The agreements between the parties involve a total fee of Rs. 8 lakh plus taxes for the grant of the licenses on a non-exclusive basis to SPL
The agreements between the parties involve a total fee of Rs. 8 lakh plus taxes for the grant of the licenses on a non-exclusive basis to SPL
In an exclusive interview with Rahul Koul of Indian Chemical News, Priyanka Chigurupati, Executive Director, Granules Pharmaceuticals Inc. USA shared details about the company's performance, R&D initiatives, Capex plan, CSR, and future outlook. Excerpts of the interview:
Emtricitabine and Tenofovir Disoproxil Fumarate tablets had estimated annual sales of US $2.1 billion in the U.S. according to IQVIA MAT March 2021
Broadens company’s oncology platform of Targeted Alpha Therapies (TATs)
Arformoterol Tartrate Inhalation Solution is for treatment of bronchoconstriction
These vaccine doses will be manufactured and stockpiled by the company from August-December 2021
Pegfilgrastim has estimated annual sales of USD 3.66 billion in the U.S. (IQVIA MAT December 2020).
Production line at Lonza’s site in Geleen will complement the existing production network and support the manufacture of up to an additional 300 million doses per year
For undertaking production, the company has been provided a Rs. 65 crore grant by the centre and Rs. 94 crore from the government of Maharashtra
This investment is being made to set up a high speed 400 vials a minute injectable fill line with isolator technology
Subscribe To Our Newsletter & Stay Updated
